HEALTHY U CHIP

PRIOR AUTHORIZATION REQUEST FORM Kevzara for Polymyalgia Rheumatica®

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

Date: Member Name: ID#:	if you have prior authorization questions, please call for Pharmacy Customer Service for assistance at 385-425-5094							
Office Phone: Office Phone: Office Fax: Office Contact: Height/Weight: Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: Preferred: corticosteroids, methotrexate Non- formulary:	Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.							
Office Phone: Office Phone: Office Fax: Office Contact: Height/Weight: Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: Preferred: corticosteroids, methotrexate Non- formulary:								
Office Phone: Office Phone: Office Fax: Office Contact: Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: Preferred: corticosteroids, methotrexate Non- formulary:	Date:		Member Name:		ID#:			
Height/Weight: Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: Preferred: corticosteroids, methotrexate	DOB:		Gender:		Phy	sician:		
Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: Preferred: corticosteroids, methotrexate Non- formulary:	Office Phone	:	Office Fax:		Office Contact:			
preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: Preferred: corticosteroids, methotrexate Non- formulary:	Height/Weigl	ht:			<u> </u>			
Questions Yes No Comments/Notes 1. Is the request made by a rheumatologist? □ Please provide documentation 2. Does the member have a diagnosis of polymyalgia rheumatic (PMR)? □ Please provide documentation 3. Has the member been taking prednisone for at least 8 weeks (≥10 mg/day or equivalent)? □ Please provide documentation 4. Does the member have clinical documentation show at least one episode of an PMR flare while attempting to taper prednisone, including both of the following: Shoulder and/or hip girdle pain associated with inflammatory stiffness Erythrocyte sedimentation rate (ESR) ≥30 mm/hr and/or C-reactive protein (CRP) ≥ 10mg/L? Please provide documentation 5. Has the member had an adequate trial and failure of methotrexate for at least 3 months? □ Please provide documentation	preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: Preferred: corticosteroids, methotrexate Non- formulary: Kevzara® (sarilumab) Note: Kevazara for the indication of RA see PHARM-HU-065							
Questions Yes No Comments/Notes 1. Is the request made by a rheumatologist? □ Please provide documentation 2. Does the member have a diagnosis of polymyalgia rheumatic (PMR)? □ Please provide documentation 3. Has the member been taking prednisone for at least 8 weeks (≥10 mg/day or equivalent)? □ Please provide documentation 4. Does the member have clinical documentation show at least one episode of an PMR flare while attempting to taper prednisone, including both of the following: Shoulder and/or hip girdle pain associated with inflammatory stiffness Erythrocyte sedimentation rate (ESR) ≥30 mm/hr and/or C-reactive protein (CRP) ≥ 10mg/L? Please provide documentation 5. Has the member had an adequate trial and failure of methotrexate for at least 3 months? □ Please provide documentation								
1. Is the request made by a rheumatologist? 2. Does the member have a diagnosis of polymyalgia rheumatic (PMR)? 3. Has the member been taking prednisone for at least 8 weeks (≥10 mg/day or equivalent)? 4. Does the member have clinical documentation show at least one episode of an PMR flare while attempting to taper prednisone, including both of the following: • Shoulder and/or hip girdle pain associated with inflammatory stiffness • Erythrocyte sedimentation rate (ESR) ≥30 mm/hr and/or C-reactive protein (CRP) ≥ 10mg/L? 5. Has the member had an adequate trial and failure of methotrexate for at least 3 months? Please provide documentation Please provide documentation Please provide documentation Please provide documentation		•	Tor readmonization, proceed	1				
2. Does the member have a diagnosis of polymyalgia rheumatic (PMR)? 3. Has the member been taking prednisone for at least 8 weeks (≥10 mg/day or equivalent)? 4. Does the member have clinical documentation show at least one episode of an PMR flare while attempting to taper prednisone, including both of the following: • Shoulder and/or hip girdle pain associated with inflammatory stiffness • Erythrocyte sedimentation rate (ESR) ≥30 mm/hr and/or C-reactive protein (CRP) ≥ 10mg/L? 5. Has the member had an adequate trial and failure of methotrexate for at least 3 months? Please provide documentation Please provide documentation Please provide documentation	1. Is the red	•	ogist?					
3. Has the member been taking prednisone for at least 8 weeks (≥10 mg/day or equivalent)? 4. Does the member have clinical documentation show at least one episode of an PMR flare while attempting to taper prednisone, including both of the following: • Shoulder and/or hip girdle pain associated with inflammatory stiffness • Erythrocyte sedimentation rate (ESR) ≥30 mm/hr and/or C-reactive protein (CRP) ≥ 10mg/L? 5. Has the member had an adequate trial and failure of methotrexate for at least 3 months? Please provide documentation Please provide documentation	2. Does the	· · · · · · · · · · · · · · · · · · ·				•		
least one episode of an PMR flare while attempting to taper prednisone, including both of the following: • Shoulder and/or hip girdle pain associated with inflammatory stiffness • Erythrocyte sedimentation rate (ESR) ≥30 mm/hr and/or C-reactive protein (CRP) ≥ 10mg/L? 5. Has the member had an adequate trial and failure of methotrexate for at least 3 months? REAUTHORIZATION	3. Has the r	<u> </u>	isone for at least 8 weeks			Please provide documentation		
methotrexate for at least 3 months? REAUTHORIZATION	least one prednisce Shou inflare	e episode of an PMR flare one, including both of the lder and/or hip girdle pa mmatory stiffness procyte sedimentation ra	while attempting to taper following: n associated with te (ESR) ≥30 mm/hr			Please provide documentation		
REAUTHORIZATION	5. Has the r	•				Please provide documentation		
				1		I .		
2. Is the requesting for reauthorization of therapy:		exace for at least 3 months		N				
	methotro		REAUTHORIZATIO	I I				

2. Does the member have clinical documentation show absence							
of signs and symptoms of PMR and CRP < 10 mg/L?							
What medications and/or treatment modalities have been tried in the past for this condition? Please document							
name of treatment, reason for failure, treatment dates, etc.							
Additional information:							
Physician Signature:							

** Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

Policy: PHARM-CHIP- 159 Origination Date: 07/01/2024 Reviewed/Revised Date: Next Review Date:

Current Effective Date: 07/01/2024

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.